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Health technology assessment in Switzerland
Abstract
OBJECTIVES AND METHODS: To review Switzerland's mixed public and private healthcare system
with regard to health technology assessment (HTA). RESULTS: In the past, remarkable work in HTA
was done. Accomplishments include the following: (i) Switzerland became an early member of the
International Network of Agencies for Health Technology Assessment. (ii) HTA has its legal bases in
terms of effectiveness, appropriateness, and efficiency. (iii) The federal law allows the introduction of
new technologies for a limited time for evaluation. (iv) A Swiss Network for Health Technology
Assessment was established. In 2004, federal HTA activities moved from the Swiss Federal Office "of
Social Security" to the one for "Public Health." The Office mainly mandates, manages, and coordinates
evaluations attached to its prevention and intervention sections in the fields of AIDS, illegal drugs, and
legal drugs. CONCLUSIONS: Because of the absence of a governmental institution assessing and
reporting on new health technologies, private and for profit organizations became more important for
the decision-making processes. In a regulated market, the implications may be crucial for the public
health.
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Objectives and Methods: To review Switzerland’s mixed public and private healthcare
system with regard to health technology assessment (HTA).
Results: In the past, remarkable work in HTA was done. Accomplishments include the
following: (i) Switzerland became an early member of the International Network of
Agencies for Health Technology Assessment. (ii) HTA has its legal bases in terms of
effectiveness, appropriateness, and efficiency. (iii) The federal law allows the introduction
of new technologies for a limited time for evaluation. (iv) A Swiss Network for Health
Technology Assessment was established. In 2004, federal HTA activities moved from the
Swiss Federal Office “of Social Security” to the one for “Public Health.” The Office mainly
mandates, manages, and coordinates evaluations attached to its prevention and
intervention sections in the fields of AIDS, illegal drugs, and legal drugs.
Conclusions: Because of the absence of a governmental institution assessing and
reporting on new health technologies, private and for profit organizations became more
important for the decision-making processes. In a regulated market, the implications may
be crucial for the public health.
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History
SWITZERLAND’S HEALTHCARE SYSTEM
IN BRIEF
Switzerland is located in central Europe with a population
in 2006 of 7.5 million inhabitants. The economy is based on
services (60 percent), followed by industry (35 percent), in-
cluding pharmaceuticals. Switzerland is a federal state com-
prising twenty-six cantons. Federal authorities carry out their
political power only in those areas explicitly delegated to
them through the cantons but the twenty-six cantons have
prime responsibility in health care and social welfare. Each
canton has its own law on health care, hygiene, hospitals, and
social welfare. These laws are not harmonized.
Switzerland has a mixed public and private healthcare
system (1). All citizens are enrolled in compulsory basic
health insurance. The public is allowed to choose among
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different sickness funds, including managed care plans. The
basic, so-called social (as distinct from private) insurance
covers all costs resulting from disease, accidents, and dis-
ability as long the client is not enrolled in a managed care
plan. Therefore, more then 80 percent of the population is
covered by either the social insurance or by private health
insurance. There is a mix of public (mainly hospitals) and
private (mainly doctors’ offices) providers. The health ser-
vices are decentralized. Ambulatory care is still traditionally
provided in doctors’ offices. In the past decade, there is a
tendency toward centers of hospitals for ambulatory care,
group practices, and managed care plans because the fi-
nancial attractiveness of doctors’ offices gets smaller over
time.
DEVELOPMENT OF HEALTH
TECHNOLOGY ASSESSMENT IN
SWITZERLAND
The continuous rises in healthcare costs for several decades
led to the realization at the federal level that action was
necessary. The development of health technology assess-
ment (HTA) in the Swiss Federal Office of Social Secu-
rity (SFOSS) was directly aimed at controlling such cost
rises.
Under the patronage of SFOSS over the past two
decades, remarkable work in the field of HTA was done.
Different types of HTA Institutions and initiatives with dif-
ferent goals, private and governmental units, were set up.
Since 1984, the principles of HTA and the way of intro-
ducing new medical technologies were continuously im-
proved and adapted to the current knowledge (2–4). Nu-
merous publications about economic evaluation of health
care technologies with comprehensive views on policy is-
sues influenced the diffusion and use of new technologies.
Membership in the International Society of Technology As-
sessment in Health Care opened the contact to the world
of HTA and its continuous evolution. Later, Switzerland
became a member of the International Network of Agen-
cies for Health Technology Assessment and EUROSCAN.
Because of these efforts, decisions for reimbursement be-
came “scientifically acknowledged” and HTA analyses were
successful.
The Federal Law of Sickness Funds (KVG) from 1994
introduced the principle that every procedure covered by so-
cial security has to be effective, appropriate, and efficient.
For emerging technologies, the interpretation of the law al-
lowed the introduction of a time-limited conditional cover-
age. The pioneering work was delivered to the HTA agendas
and was recognized worldwide. The introduction of Evalua-
tion Registries to monitor the temporary insurance coverage
followed. In 2000, the Swiss Network for HTA (SNHTA:
www.snhta.ch) to coordinate and promote HTA projects in
Switzerland was founded.
The Coverage Process by the Federal
Social Security Office (SFOSS)
The application procedure for reimbursement of a new med-
ical service requires a minimum amount of information that
will enable the Swiss Federal Office of Public Health (FOPH)
to assess the procedure in terms of its effectiveness, appropri-
ateness/safety, and efficiency (original terms Wirksamkeit,
Zweckma¨ssigkeit, Wirtschaftlichkeit) (1;5). A new Hand-
book for reimbursement procedure was presented in May
2008 by Swiss Federal Office in Bern, Switzerland, and is in
use since then.
The health insurers and the organizations of physicians
are asked if the procedure is established or controversial.
If both state that the procedure is established, it is gen-
erally covered. If either or both states that the procedure
(the technology) is controversial, there is an organized pro-
cess of assessment and gathering opinions before a cover-
age decision is made. An information synthesis on known
efficacy, effectiveness, and safety is carried out, as well as
collection of information on economic, legal, ethical aspects,
drawn from the scientific literature and Swiss and foreign re-
ports. If such information is available from Swiss registries,
data on utilization, outcome, side effects, cost, manpower
considerations, and technical aspects are also part of the
process.
The Development of Other HTA Programs
In 2004, all federal HTA activities except for those directly
related to coverage moved from SFOSS to the Swiss FOPH
(5). The Office is principally involved in health protection
and controlling activities. However, since 1980, the Office
has a leading role in promoting preventive measures to stop
the spread of the HIV/AIDS epidemic. Its overall mission is
to ensure its population a healthy living standard. It measures
the impact of its actions in terms of the overall development
of the nation’s health. An evaluation service was set up in the
Medical Division 1993 to mandate, manage, and coordinate
evaluation studies, attached to the Office’s prevention and
intervention sections in the fields of AIDS, illegal drugs,
and legal drugs. Since then, the evaluation function has been
institutionalized at the federal level (7).
The Swiss Centre for Technology Assessment (TA-
SWISS) was founded in 1992 (6). TA-SWISS analyses
chances and risks of new technological developments. Spe-
cial attention is given to the fields of “biotechnology and
medicine” and “the information society and nanotechnolo-
gies.” TA-SWISS fulfils its task of providing advice to policy
makers by means of expert studies and participative methods
(participation with the general public). Its interdisciplinary
studies are authored by experts and easy to understand: sum-
maries are elaborated and addressed to decision makers and
the general public. The same applies to the recommendations
and results obtained from participative methods (6,8).
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PRIVATE INSTITUTES AND EXAMPLES
In the absence of a publicly funded system for assessing
and reporting new health technologies, the Swiss healthcare
market commonly uses reports from externally funded HTA
agencies of high reputation (e.g., Ontario Health Technology
Advisory Committee, National Institute for Clinical Excel-
lence, etc.), together with reports from Swiss independent
private organizations for decision-making processes. ICHI
(www.ichi.ch), is an example of an organization that creates
a forum for solving reimbursement issues where dialogue
between companies who have developed new medical tech-
nologies and the respective medical societies leads to suc-
cessful reimbursement strategies through HTA. A main goal
is bringing all stakeholders together to find solutions to trans-
fer innovative medical devices to the market. ICHI GmbH
offers an integrated team of experts that regularly prepares
HTAs together with reimbursement dossiers for submission
to the Swiss FOPH (9).
As an example, in 1998 the Federal Department of Home
Affairs requested a program for the evaluation of comple-
mentary medicine (10). Five complementary therapies such
as traditional Chinese methods, homeopathy, or herbal ther-
apy were included for a limited time for reimbursement (July
1, 1999, until June 30, 2005). In a difficult process, seek-
ing consensus among representatives of different interest
groups, a basic evaluation procedure was defined, compris-
ing two parts: The evaluation conducted empirical studies and
HTA (literature analysis including efficacy, appropriateness,
safety, utilization, and cost-effectiveness). Despite positive
results for some complementary methods, all of them were
omitted from reimbursement at the end of the program by
a political decision of the Swiss FOPH. The Ministerial de-
cision was not accepted either by Swiss citizens or by the
Swiss parliament. It is expected to be changed due to public
pressure in 2009.
DISCUSSION
All healthcare systems are managed to some extent, and
access to health technology is directly influenced by pric-
ing decisions of governments. However, whatever tech-
nology appears and is used, eventually coverage will be
given as long as peer—and public—pressure is present.
Therefore, HTA may play a secondary role in coverage
decisions.
Most probably because of an organizational change
within governmental structures over the past 5 years, knowl-
edge in the field of HTA is perhaps still present, but inno-
vation has been transferred to private initiatives. The hidden
consequences, if ignored by policy makers and healthcare
professionals, may be crucial. In a regulated market driven
without respect for HTA, different influences may seriously
damage public health.
With the move of most Federal HTA activities to FOPH,
the broad perspective of HTA seen in earlier days was some-
what lost. The FOPH activities, as stated, concern themselves
mainly with HIV/AIDS and legal and illegal drugs. The im-
plications of health technology in general are not visibly as-
sessed, because if such assessments are done, they are done
in a less visible way.
The main point is, that because health care is mainly
an issue for the Swiss cantons, the federal government
is largely not involved with most health technology. Ear-
lier, the program in SFOSS concerned itself with all HTA
and acted as a kind of force for coordination. There also
were some Cantonal HTAs. However, cantons no longer do
HTAs.
Switzerland probably needs a national agency of HTA
such as those developed in most members of INAHTA. As
seen also in the Netherlands (see study in this issue), the lack
of a national approach and a requirement for coordination and
communication of all HTA results has led to some duplication
and considerable gaps in the concerns for health technology,
at least as far as is known. Hopefully, this problem can be
addressed during the next few years.
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